3D-conformal palliative radiation therapy plus toceranib (Palladia®) for the treatment of measurable carcinomas in the dog

Description

The goal of this study is to evaluate therapy with toceranib (Palladia®), an oral anticancer agent, in combination with palliative radiation therapy for tolerability, toxicity, and efficacy in a population of dogs with measurable carcinomas. Carcinomas are a common malignancy in both dogs and humans. As a category of cancer, carcinomas tend to be both locally invasive as well as carry a high risk of locoregional metastasis. While most dogs diagnosed in early stages may respond well to multimodality therapy, survival is generally thought to be shorter for bulky or metastatic tumors. New treatments for advanced carcinomas are needed to improve patient comfort and survival.

Inclusion Criteria

Dogs with cytologic or histology confirmation of the following carcinomas are eligible to participate in this study: anal sac adenocarcinoma, ceruminous gland carcinoma, mammary gland carcinoma, nasal carcinoma, prostatic carcinoma, salivary gland carcinoma, sebaceous adenocarcinoma, squamous cell carcinoma, rectal carcinoma, thyroid carcinoma, or transitional cell carcinoma of the urethra. The patient must have measurable disease at the primary tumor site and/or metastatic lymph nodes. Dogs should be otherwise in good health, a candidate for 10 daily anesthetic episodes, and must have adequate organ function as determined by blood work and urinalysis. Previous chemotherapy or surgery is allowable provided it is a minimum of 2 weeks prior to enrollment in the trial. Prior NSAID therapy is allowed if the patient has been on this therapy for minimum of 2 weeks prior to enrollment. Any homeopathic/alternative therapies for cancer must be discontinued prior to enrollment.

Exclusion Criteria

The following carcinomas are ineligible for participation: adrenocortical carcinoma, gastrointestinal carcinoma (excluding rectal), renal carcinoma, or transitional cell carcinoma of the urinary bladder. Dogs are also ineligible if they have received prior radiation therapy to the tumor site.

Client Benefits

Clients participating in this study will be given special financial considerations. Specifically, the study will cover the following costs associated with participation in this clinical trial: the cost of Palladia for 12 weeks, $1250 towards radiation therapy, one set of chest x-rays (at week 12), and recheck exam fees at week 3, 4, 6, and 12 of the study. This amounts to a total financial benefit of approximately $2200.

The client will be responsible for general anesthesia and costs for the CT scan (if required); all radiation therapy costs beyond $1250; all costs associated with monitoring blood work and urinalyses during the study period and beyond; and any diagnostic tests (x-rays, abdominal ultrasound, etc.) and recheck exam fees beyond week 12. The client is expected to make and keep all appointments, according to the clinical trial protocol once enrolled.

Contact Information

Kelly Reed, Oncology Liaison
Phone: (508) 887-4682